Skip to main content

Advertisement

SpringerLink
Log in

Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib

  • Research Letter
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. V. Marotta, C. Sciammarella, M. Vitale, A. Colao, A. Faggiano, The evolving field of kinase inhibitors in thyroid cancer. Crit. Rev. Oncol. Hematol. (2014). doi:10.1016/j.critrevonc.2014.08.007

    PubMed  Google Scholar 

  2. A.L. Ho, Moving toward a better understanding of radioiodine action. Endocrine 44(3), 553–554 (2013). doi:10.1007/s12020-013-0024-x

    Article  CAS  PubMed  Google Scholar 

  3. V. Marotta, M.D. Franzese, M. Del Prete, M.G. Chiofalo, V. Ramundo, R. Esposito, F. Marciello, L. Pezzullo, A. Carratu, M. Vitale, A. Colao, A. Faggiano, Targeted therapy with kinase inhibitors in aggressive endocrine tumors. Expert Opin. Pharmacother. 14(9), 1187–1203 (2013). doi:10.1517/14656566.2013.796931

    Article  CAS  PubMed  Google Scholar 

  4. R.T. Kloos, M.D. Ringel, M.V. Knopp, N.C. Hall, M. King, R. Stevens, J. Liang, P.E. Wakely Jr, V.V. Vasko, M. Saji, J. Rittenberry, L. Wei, D. Arbogast, M. Collamore, J.J. Wright, M. Grever, M.H. Shah, Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27(10), 1675–1684 (2009). doi:10.1200/JCO.2008.18.2717

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. V. Marotta, V. Ramundo, L. Camera, M.D. Prete, R. Fonti, R. Esposito, G. Palmieri, M. Salvatore, M. Vitale, A. Colao, A. Faggiano, Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf) (2012). doi:10.1111/cen.12057

    Google Scholar 

  6. V. Gupta-Abramson, A.B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger, K. Ransone, S.J. Mandel, K.T. Flaherty, L.A. Loevner, P.J. O’Dwyer, M.S. Brose, Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714–4719 (2008). doi:10.1200/JCO.2008.16.3279

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. M.E. Cabanillas, S.G. Waguespack, Y. Bronstein, M.D. Williams, L. Feng, M. Hernandez, A. Lopez, S.I. Sherman, N.L. Busaidy, Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J. Clin. Endocrinol. Metab. 95(6), 2588–2595 (2010). doi:10.1210/jc.2009-1923

    Article  CAS  PubMed  Google Scholar 

  8. H. Hoftijzer, K.A. Heemstra, H. Morreau, M.P. Stokkel, E.P. Corssmit, H. Gelderblom, K. Weijers, A.M. Pereira, M. Huijberts, E. Kapiteijn, J.A. Romijn, J.W. Smit, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161(6), 923–931 (2009). doi:10.1530/EJE-09-0702

    Article  CAS  PubMed  Google Scholar 

  9. M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Pena, I. Molnar, M.J. Schlumberger, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (2014). doi:10.1016/S0140-6736(14)60421-9

    PubMed Central  Google Scholar 

  10. S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, J.P. Armand, P. Scigalla, E. Raymond, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24(1), 25–35 (2006). doi:10.1200/JCO.2005.02.2194

    Article  CAS  PubMed  Google Scholar 

  11. L.L. Carr, D.A. Mankoff, B.H. Goulart, K.D. Eaton, P.T. Capell, E.M. Kell, J.E. Bauman, R.G. Martins, Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 16(21), 5260–5268 (2010). doi:10.1158/1078-0432.CCR-10-0994

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. J.J. Diez, P. Iglesias, T. Alonso, E. Grande, Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice. Endocrine (2014). doi:10.1007/s12020-014-0356-1

    Google Scholar 

  13. E.E. Cohen, B.M. Needles, K. J.Cullen, S. J.Wong, J. L.Wade III, S. P.Ivy, V. M.Villaflor, T. Y.Seiwert, K.Nichols, E. E.Vokes: Phase 2 study of sunitinib in refractory thyroid cancer. J Clini Oncol, ASCO Annual Meeting Proceedings 26(15S) (2008)

  14. P. Kaldrymides, I. Kostoglou-Athanassiou, A. Gkountouvas, E. Veniou, N. Ziras, Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature. Endocrine 37(1), 6–10 (2010). doi:10.1007/s12020-009-9290-z

    Article  CAS  PubMed  Google Scholar 

  15. T.E. Hutson, R.M. Bukowski, C.L. Cowey, R. Figlin, B. Escudier, C.N. Sternberg, Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48–62 (2011). doi:10.1016/j.critrevonc.2010.07.018

    Article  PubMed  Google Scholar 

  16. M. Xing, B.R. Haugen, M. Schlumberger, Progress in molecular-based management of differentiated thyroid cancer. Lancet 381(9871), 1058–1069 (2013). doi:10.1016/S0140-6736(13)60109-9

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009). doi:10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  18. R. Dadu, C. Devine, M. Hernandez, S.G. Waguespack, N.L. Busaidy, M.I. Hu, C. Jimenez, M.A. Habra, R.V. Sellin, A.K. Ying, G.J. Cote, S.I. Sherman, M.E. Cabanillas, Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J. Clin. Endocrinol. Metab. 99(6), 2086–2094 (2014). doi:10.1210/jc.2013-3588

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. S. Faivre, M. Zappa, V. Vilgrain, E. Boucher, J.Y. Douillard, H.Y. Lim, J.S. Kim, S.A. Im, Y.K. Kang, M. Bouattour, S. Dokmak, C. Dreyer, M.P. Sablin, C. Serrate, A.L. Cheng, S. Lanzalone, X. Lin, M.J. Lechuga, E. Raymond, Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin. Cancer Res. 17(13), 4504–4512 (2011). doi:10.1158/1078-0432.CCR-10-1708

    Article  CAS  PubMed  Google Scholar 

  20. Y. Mizukami, Y. Kohgo, D.C. Chung, Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin. Cancer Res. 13(19), 5670–5674 (2007). doi:10.1158/1078-0432.CCR-07-0111

    Article  CAS  PubMed  Google Scholar 

  21. H.X. Chen, J.N. Cleck, Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8), 465–477 (2009). doi:10.1038/nrclinonc.2009.94

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. Nothing to declare about financial disclosure.

Author information

Authors and Affiliations

  1. Department of Clinical Medicine and Surgery, Section of Endocrinology, Federico II University of Naples, Via S. Pansini 5, 80131, Naples, Italy

    Vincenzo Marotta, Manila Rubino, Concetta Sciammarella, Roberta Modica, Michela Del Prete, Francesca Marciello, Valeria Ramundo, Pasqualina Buonomano, Annamaria Colao & Antongiulio Faggiano

  2. IRCCS SDN, Naples, Italy

    Carolina Di Somma

  3. Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy

    Luigi Camera

  4. National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy

    Luisa Circelli & Antongiulio Faggiano

Authors
  1. Vincenzo Marotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolina Di Somma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manila Rubino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Concetta Sciammarella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberta Modica
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luigi Camera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michela Del Prete
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francesca Marciello
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Valeria Ramundo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Luisa Circelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pasqualina Buonomano
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Annamaria Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Antongiulio Faggiano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Marotta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marotta, V., Di Somma, C., Rubino, M. et al. Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. Endocrine 49, 854–858 (2015). https://doi.org/10.1007/s12020-014-0448-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0448-y

Keywords

Search

Navigation